Epirubicin Market Size - Global Analysis Report 2022 - 2028

The epirubicin market is projected to reach US$ 243.99 million by 2028 from US$ 191.66 million in 2021; it is expected to register a CAGR of 3.60% from 2022 to 2028.

Epirubicin is an anthracycline medicine with the first clinical trial published in 1980. The drug was designed to be favored over doxorubicin because of better efficacity and quality. It is used for chemotherapy purposes for the treatment of various cancers. The drug is prescribed alone or in combination for the primary use against breast cancer, ovarian cancer, liver cancer, bladder cancer, and others. The product works by slowing or stopping the growth of cancer cells in the body. Combination therapies include fluorouracil, epirubicin hydrochloride, and cyclophosphamide (FEC), in which the product is given along with fluorouracil and cyclophosphamide. Adjuvant therapy of epirubicin seems to be less toxic compared to monotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. In August 2007, the product lost its patent and became generic. The product shows the limited scope in cancer treatment due to its side effects. The common side effect was the heart, bone marrow, and blood.

Epirubicin (EPI) was successfully incorporated into a solid-liquid nanoparticle formulation to produce a stable inhalable nebulized suspension for treating lung cancer.

Strategic Insights

The epirubicin market  is segmented based on dosage, application, distribution channel, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends and market dynamics and the competitive analysis of the globally leading market players.

Lucrative Regions for Epirubicin Market

Get more information on this report : Request Free Sample PDF

Market Insights

Rising Prevalence of Cancer

Epirubicin is an anticancer drug that falls under the category of anthracyclines and is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy has removed most of them.

According to the American Cancer Society, the global burden of cancer is estimated to have risen to 19.3 thousand new cases in 2021 and 10.0 thousand deaths in 2020. As per the National Cancer Institute (US), an increase in the incidence and prevalence of cancer has a significant impact on society globally. According to stats by the institute, in the US, nearly 1.8 thousand people were diagnosed with cancer, and about 606,520 people developed the disease in 2020. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. According to the Centers for Disease Control and Prevention (CDC), each year in the US, about 24,500 men and 10,000 women get liver cancer, and about 18,600 men and 9,000 women die from the disease. The percentage of Americans who get liver cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the US. Hence, the rising prevalence of cancer cases is driving the epirubicin market.

The healthcare industry in the Middle East & Africa region is still developing; hence, they faced the biggest challenge due to the COVID-19 pandemic. Health authorities were worried that attempting to fight COVID-19 would indirectly contribute to an increase in deaths of ill patients, including cancer patients. The death pool of ill patients in low-cost regions was expected to increase because healthcare professionals limited their patient appointments as many hospitals had limited resources and staff.

However, the launch of COVID vaccination programs in the year 2021, in several countries controlled the situation. These efforts to control the spread will ultimately recover and restore the situations post-pandemic.

Examples of development that have promoted the growth of the epirubicin market are listed below:

• In April 2018, Hikma Pharmaceuticals PLC (Hikma, Group) announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), had launched Epirubicin Hydrochloride Injection, USP in 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence. West-Ward’s Epirubicin Hydrochloride Injection, USP is a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Epirubicin Market - Application Insights

Based on application, the epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and other cancer. The breast cancer segment held the largest share of the market in 2021. The breast cancer segment is anticipated to register the highest CAGR in the market during the forecast period and the same segment is anticipated to register the highest CAGR during the forecast period. In the 1970s, epirubicin was launched as a drug to treat metastatic breast cancer, and at present, it is among the most active single agents treating breast cancer. Medicine can be used at an early stage of breast cancer to reduce the chances of breast cancer reoccurrence. It is widely used as adjuvant therapy for those who have had surgery and lymph nodes. Hence, in most cases, the medicine is usually prescribed with other medicines. In some instances, it can be used as a substitute for doxorubicin (Adriamycin) as it may cause less heart damage than doxorubicin. The medicine is injected into a vein and is often given once every three weeks or twice every 28 days for 6 cycles. The drug is made available in the market by Pfizer, Inc., and Sandoz (a Novartis AG Division), among others. There has been constant development in cancer therapeutics; hence, various companies are launching products in the market. For instance, in April 2018, Hikma Pharmaceuticals PLC launched Epirubicin Hydrochloride Injection, USP, in variants such as 50mg/25mL and 200mg/100mL vials. The product is the generic version and is equivalent to Ellence. Thus, product availability and product launches in the market are likely to enhance the market's growth during the forecast period.

Epirubicin Market, by Application – 2021 and 2028

Get more information on this report : Request Free Sample PDF

Epirubicin Market - Dosage Insights

Based on dosage, the global epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest share of the market in 2021; however, the 100mg/vial segment is anticipated to register the highest CAGR during the forecast period. Epirubicin 50 mg injection is an anticancer agent which is used as an adjuvant drug to treat breast cancer. It is vesicant and should be injected into veins under the supervision of qualified physicians. The effect of 10 mg epirubicin lasts for an average of 3 to 4 days. Market players operating in the epirubicin market are offering epirubicin in different dosages. For instance, Pfizer is offering epirubicin hydrochloride in 10 mg and 50 mg dosages.

Epirubicin Market - Distribution Channel Insights

Based on distribution channel, the global epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2021. The same segment is anticipated to register the highest CAGR of 4.0% in the market during the forecast period. Hospital pharmacies are an integral aspect of patient care at a healthcare facility. Hospital pharmacy is the field that works to consistently uphold and enhance patient pharmaceutical care and medication management to the highest standards possible in a hospital setting. The hospital pharmacy is one of the primary areas in hospitals where pharmaceuticals are purchased, stored, compounded, dispensed, manufactured, tested, packaged, and distributed. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. The selection, prescription, procurement, delivery, administration, and review of pharmaceuticals are among the objectives that aim to improve patient outcomes.

Epirubicin Market – by Region

By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).  

Epirubicin Market - Company Profiles

The epirubicin market majorly consists of players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.